早产儿异基因细胞移植免疫耐受的研究进展  

Research advances in immune tolerance of allogeneic cell transplantation in preterm infants

作　　者：吕灿 屈艺 母得志 LYU Can, QU Yi, MU De-Zhi(Department of Pediatrics, West China Second University Hospital/Key Laboratory of Birth Defects and Related Diseases of Women and Children （Sichuan University）, Ministry of Education, Chengdu 610041, China)

机构地区：[1]四川大学华西第二医院儿科/出生缺陷与相关妇儿疾病教育部重点实验室,四川成都610041

出　　处：《中国当代儿科杂志》2018年第4期338-340,F0003,共4页Chinese Journal of Contemporary Pediatrics

基　　金：国家重点研发计划项目(2017YFA0104204)

摘　　要：早产儿是一类特殊的群体,与早产相关的严重神经、呼吸、消化系统疾病的致残/致死率居高不下。异基因细胞移植可能是上述疾病治疗和预防的有效手段。目前,异基因细胞移植治疗缺氧缺血性脑病、支气管肺发育不良以及坏死性小肠结肠炎的动物实验已成功开展。而异基因细胞移植治疗早产儿疾病所面临的困难主要是移植物抗宿主反应,而要解决这一问题,需要实现免疫耐受的成功诱导。本文就近年来早产儿异基因细胞移植免疫耐受的研究进展进行综述。Preterm infants are a special group, and related severe neurological, respiratory, and digestive disorders have high disability/fatality rates. Allogeneic cell transplantation may be an effective method for the prevention and treatment of these diseases. At present, animal studies have been conducted for allogeneic cell transplantation in the treatment of hypoxic-ischemic encephalopathy, bronchopulmonary dysplasia, and necrotizing enterocolitis. The main difficulty of this technique is graft-versus-host reaction（GVHR）, and successful induction of immune tolerance needs to be achieved in order to solve this problem. This article reviews the research advances in immune tolerance of allogeneic cell transplantation in preterm infants.

关 键 词：异基因细胞移植 移植物抗宿主反应 免疫耐受 早产儿 

分 类 号：R722.6[医药卫生—儿科]